knowledge -WSS

knowledge

author：knowledge 2025-10-04 10:02:12 - browse：37224

Joaquin Duato -- health policy coverage from STAT — Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

“The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

WSS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

NIH tests clinical research in primary care with $30 million program

The system is set up to fail children with medical complexity

NEJM study link tiny plastics in blood vessels to heart problems

5 takeaways from STAT's examination of Zynex Medical

My daughter's legacy lives on through her writing, phage therapy

focus

knowledge

Wikipedia

How one medical school became remarkably diverse

The Readout: Amylyx, Alumis, and Lundbeck drug updates

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Alkermes shareholders re

Novo Nordisk obesity pill bests Wegovy in early trial

Hepatitis C has a cure — but many Americans still lack access to it

Sen. Paul opposes bill to ban Chinese biotechs

Duchenne breakthrough therapy leaves behind pioneering families

Amylyx ALS drug failure raises questions and concerns

focus

Study: Why relieving medical debt did not improve financial outcomes

With psoriasis trial ahead, Alumis raises $259 million

With psoriasis trial ahead, Alumis raises $259 million

Medical device trials still don't enroll enough women, study finds

Change Healthcare payments predicted restored March 15

Coercive sterilizations revealed by STAT prompt outrage

focus

explore

knowledge

focus